GPA
VRTX icon

Guidance Point Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Guidance Point Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200
Closed -$36K – 398
2021
Q3 		$36K Buy
+200
New +$39K 0.01% 170

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Guidance Point Advisors's VRTX Position: Q4 2021 in Review

Guidance Point Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 200 shares — an estimated $36K sold.

Guidance Point Advisors first reported a position in VRTX in Q3 2021 and held it in 1 quarter. The position peaked at $36K in Q3 2021. 1,033 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • Guidance Point Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Guidance Point Advisors sold 200 Vertex Pharmaceuticals shares in Q4 2021, an estimated $36K.
  • Guidance Point Advisors first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Guidance Point Advisors's Vertex Pharmaceuticals position peaked at $36K in Q3 2021.
  • 1,033 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Guidance Point Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.